An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

• Status: Recruiting
• Trial end date: 2022-09-01

Summary

This study is a pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer. More specifically, this is a randomized, multi-center, open label, phase II study for Homologous Recombination Deficiency(HRD)+ patients and a biomarker-driven multiple-arm phase II study for Homologous Recombination Deficiency(HRD)- patients.

This study will consist of a number of study modules (substudies), each evaluating the antitumor activity of targeted agents in patients whose tumors express specific phenotype relevant to the molecules under investigation.

• Phase: Phase 2

Details

• Lead Sponsor: Yonsei University
• Collaborators: AstraZeneca; Korean Gynecologic Oncology Group; Samsung Genomic Institute; Samsung Medical Center; Seoul National University Hospital
• Treatments: Antibodies, Monoclonal; Cediranib; Doxorubicin; Durvalumab; Liposomal doxorubicin; Olaparib; Paclitaxel; Tremelimumab